Piramal Phytocare Ltd. - (Amalgamated) Stock Analysis

BSE: 532979 | NSE: PIRPHYTO | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 10-Dec-2019 18:01
22.55 0.00 (0.00%)

DeciZen - Make an Informed Decision on Piramal Phyt-Amalga

M-Cap below 100cr DeciZen not available

Piramal Phyt-Amalga Price Chart

P/E Ratio ( SA) :
Market Cap :
58.5 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

The key valuation ratios of Piramal Phytocare Ltd. - (Amalgamated)'s currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Piramal Phyt-Amalga:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % -75.6%-61.6%-6.7%-33.3%-30.4%-34.6%-49.2%3.8%363%52.2%-
Value Creation Index NANA-1.5-3.4-3.2-3.5-4.5-0.7NANA-

Growth Parameters

Growth Parameters Colour Code Guide

YoY Gr. Rt. %-156.2%-82%83.9%13.7%-23.8%39.2%-34.7%476.5%5.5%-
Adj EPS -50.9-56.1-2.8-2.5-1.6-1.3-1.30.1-8.7-3.2-3.7
YoY Gr. Rt. %-NANANANANANANA-12457.1%NA-
BVPS (₹) -58.4-
Adj Net Profit -130-143-7.2-6.4-4.2-3.5-3.30.2-22.5-8.2-10
Cash Flow from Ops. -118-99.2-1.7-
Debt/CF from Ops. -2.8-4.90-0.100000-1-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 16.9%33.3%58.4%5.5%
BVPS 0-216.8-272.40
Share Price -3.3% -12.9% - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 156.365.55.4-33.7-30.7-34.6-49.23.8363.238.334.1
Op. Profit Mgn % -1631.8-587.4-99-462.717.918-1.3-95-29.8-35.9
Net Profit Mgn % -2099.8-903.3-253.9-123-71.2-76.4-51.64.6-94.3-32.8-42.2
Debt to Equity -2.2-1.70000000-0.5-
Working Cap Days 7034271,580205136197157227649095
Cash Conv. Cycle 678023710577117991047-1230

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Piramal Phytocare Ltd. - (Amalgamated)

Standalone Consolidated
TTM EPS (₹) -3.7 -
TTM Sales (₹ Cr.) 23 -
BVPS (₹.) -12.1 -
Reserves (₹ Cr.) -57 -
P/BV -1.86 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 22.40 / 24.55
All Time Low / High (₹) 3.40 / 519.80
Market Cap (₹ Cr.) 58.5
Equity (₹ Cr.) 26
Face Value (₹) 10
Industry PE 36.3

Management X-Ray of Piramal Phyt-Amalga :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Piramal Phyt-Amalga

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Piramal Phytocare Ltd. - (Amalgamated) FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Piramal Phyt-Amalga on 10-Dec-2019 18:01 is : 22.55.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Dec-2019 18:01 the market cap of Piramal Phyt-Amalga stood at ₹ 58.54.
The latest PE ratio of Piramal Phyt-Amalga as of 10-Dec-2019 18:01 is 0.00.
The latest PB ratio of Piramal Phyt-Amalga as of 10-Dec-2019 18:01 is -1.86
The 52-week high of Piramal Phyt-Amalga is ₹ 24.55 and the 52-week low is ₹ 22.40.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Piramal Phyt-Amalga is ₹ 23.01 ( Cr.) .

About Piramal Phytocare Ltd. - (Amalgamated)

Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.

PLSL is focused on four therapeutic areas - Cancer, Diabetes, Inflammation and Infectious Diseases. The company has a pipeline of fourteen compounds, including four in clinical trials. PLSL's lead chemical compound, a Cdk-4 inhibitor, has completed two Phase I studies and is being tested in another Phase I/II trial for Multiple Myeloma. PLSL has drug discovery and development agreements with Eli Lilly & Company and Merck & Company, two of the leading pharmaceutical companies in the world.

PLSL has been listed on the National Stock Exchange and the Bombay Stock Exchange since June 2008.

PLSL partners with leading Indian educational institutes to form a research collaborations namely Anna University, Chennai, Indian Institute of Science, Bangalore, Regional Research Laboratory, Jammu, Central Drug Research Institute, Lucknow, National Institute of Immunology, Delhi, National Institute of Oceanography, Goa, and Indian Institute of Chemical Biology, Kolkata.

The company has fourteen compounds in pipeline that includes four in clinical trials. PLSL’s lead chemical compound a Cdk-4 inhibitor has successfully completed two phase studies and will be tested in another Phase I/II trials.

The company has a number of molecules in its research pipeline - in oncology (biological targets: Cyclin Dependent Kinase Cell Cycle inhibitors, Hypoxia Inducible Factor-1a (HIF-1a) Inhibitors, PI3 Kinase Inhibitors), inflammation (TNF - Production / Release Inhibitors, Safer NSAIDs), diabetes (Insulin Sensitizers [non-PPAR], GPR40 Modulators) and infectious disease (Microbial extracts: Antibacterial, Microbial extracts: Antifungal). PLSL also has a comprehensive library of plant extracts and microbial strains.

Research Activities

The company’s research vision and strategy is based on three core principles:Provide scientists state-of-the-art infrastructure to produce world-class science. Leverage India’s bio-diversity and wealth of knowledge on traditional systems of medicines to source drug lead molecules. And collaborate with academic institutions. Following are the research activities:

  • Molecular Biology
  • Biomarker Discovery
  • Medicinal and Synthetic Chemistry
  • Polymer Chemistry
  • Analytical Chemistry
  • Natural Products
  • Herbal Extraction
  • HTS Group
  • Oncology
  • Inflammation
  • Diabetes
  • Vaccine
  • Special Projects
  • Clinical Development
  • Business Development
  • In-vivo Pharmacology
  • Discovery Informatics

Awards & Achievements

  • Dr. Somnath Halder, Group Leader - Medicinal Chemistry, Piramal Life Sciences Limited, wins InnoCentive award for a novel idea to solve a Synthetic Ideation Challenge for an efficient synthesis of vinyl glycine or its hydroxy analogue
  • Dr. Kalpana Joshi, Vice President - Target identification, Piramal Life Sciences Limited, wins the 'Lokmat Maharashtrian of the Year' award for Science and Technology.



  • The company gets listed in the NSE and BSE
  • The company entered into a collaboration agreement with Pierre Fabre Laboratories for research in oncology
  • The company made an oral presentation during the 68th Scientific Session of the American Diabetes Association (ADA) being convened at San Francisco, California, USA. The presentation was on preclinical pharmacological data pertaining to a novel, orally active glucose-lowering compound, P1736, discovered and developed at Piramal Life Sciences, Mumbai, using their proprietary insulin resistance cell model.
  • Industry-University/National institutes partnership, were industry and academia will work together to screen such a large number of bacterial isolates. Different academic institutes will isolate organisms’ specific to diverse ecological niches.
  • The company received regulatory approval for the initiation of a Phase I study of a new cancer compound, P-1446A-05, in Canada.
  • The company received regulatory approval for the initiation of a phase-I study in India by Drug Controller General of India (DCGI) of a new cancer compound, P-1446A-05.
  • The company started its Phase II trial of P276 for head and neck cancer


  • The company started phase II trial in USA for its lead cancer compound P 276-00 to treat Mantle cell Lymphoma (MCL) and it is the second IND approved by the US FDA for this compound.
  • The company received regulatory approval by Drug Controller General of India (DCGI) for the initiation of two phase-I/II combination studies of its cancer molecule P276 for pancreatic and head and neck cancer.
  • The company commenced Phase I trial of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada.
  • The company completed Phase I Trials with a New Molecule for Type II Diabetes in Europe
  • The company made a presentation during the 49th Scientific Session of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being convened at San Francisco, California, USA


  • The company introduced Tinefcon, its newly developed natural remedy for Psoriasis at American Academy of Dermatology Convention in Miami, USA


  • The Department of Biotechnology (DBT), Government of India and Piramal Life Sciences Limited (PLSL) have begun Phase II of their Drug Discovery Public Private Partnership to find new drugs from 14000 bioactive cultures discovered in a nationwide search for new drugs from biodiverse habitats across the country in collaboration with 9 national institutes.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now